Abstract
METex14 skipping is an oncogenic driver in patients with NSCLC; biomarker testing is vital to identify patients who would benefit from targeted therapy with MET inhibitors. We conducted a systematic literature review to gain better understanding of the epidemiology of this rare alteration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
